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Background: Parents often experience stress-related complications when their child requires blood and marrow
transplant (BMT). Previous studies have described the emotional toll BMT places on parents during the acute phase
of care and within the context of clinical complications. In this paper we introduce the Parent Impact Scale (PARimpact),
designed to capture physical and emotional challenges of the child’s health on the parent. The primary aim of this
paper is to examine psychometric properties of PARimpact, and the secondary aim is to explore factors associated with
PARimpact scores for further hypothesis generation.
Methods: This analysis used a merged dataset of two longitudinal studies. Accompanying parents (n = 363) of children
undergoing BMT were surveyed up to six times from pre-BMT baseline to one year after their child’s BMT. For
this analysis, pre-BMT baseline responses to PARimpact were used to examine the factor structure with Principal
Component Analysis (PCA) and Exploratory Factor Analysis (EFA). Construct validity was assessed, and multivariable
regression was used to examine relationships between PARimpact and BMT clinical variables.
Results: PCA and EFA revealed a one-factor solution with acceptable item loading; Cronbach’s α was 0.83 at baseline.
Hypothesized differences in known groups were detected for BMT complications with significantly higher PARimpact
scores for those with vs. without each complication. In the adjusted multivariable regression models, acute graft
versus host disease (b = 5.3; p = 0.03), end organ toxicity (b = 5.9; p < 0.01), and systemic infection (b = 9.1; p < 0.01)
were associated with significantly higher mean PARimpact scores in the first 3 months following transplant. After the
first 3 months to 1 year post BMT, systemic infection was associated with increased mean PARimpact scores (b = 19.2;
p < 0.01).
Conclusions: Initial results suggest that the PARimpact is valid and reliable. Our finding that clinical complications
increase the impact of BMT on the caretaking parent indicates the need for BMT healthcare professionals to identify
these events and help parents navigate the BMT course. Clinical application of the PARimpact scale should be
considered to identify high-risk families and provide targeted interventions to augment care.
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Blood and marrow transplant (BMT) offers children
with life-threatening illness, and their families, hope of
durable cure when no other curative treatment is avail-
able [1]. However, parents of children undergoing BMT
often experience a great deal of stress [2], and are at risk
for short and long-term psychosocial sequelae, such as
depression, anxiety, post-traumatic stress symptoms, and
decreased quality of life (QOL) [3-6]. While some pro-
spective studies have shown that parental well-being is
most affected during the acute phase of the BMT and
then improves with time, there is evidence that the pat-
tern is more nuanced, and is related to other variables,
such as previous emotional history and the clinical com-
plications of the BMT [5,7-10]. Furthermore, retrospect-
ive studies show some bereaved and non-bereaved
parents continue to experience distress for years after
the BMT [11-13].
Enhancing our understanding of the parent, family,
and BMT characteristics that are associated with in-
creased parental impact may help clinicians identify
parents most at risk, and lead to the development of
interventions to support parents through the BMT
trajectory. In one study of 49 parents/guardians of
BMT recipients, 81% of parents/guardians reported
they felt proceeding to BMT was their only choice,
given its life-saving potential [14]. Because of the
high stakes and demands of the treatment, support
for these potentially vulnerable parent caregivers is
paramount.
Previous research has documented that parental dis-
tress [9] and diminished parent emotional functioning
are associated with BMT [7]. What has not been de-
scribed is the direct effect of the child’s emotional and
physical condition on parents, and their ability to man-
age other obligations, such as work. In this paper we
introduce the Parent Impact Scale (PARimpact), a scale
within the Child Health Ratings Inventories (CHRIs),
[15] designed to capture the physical and emotional im-
pact of the child’s health condition on the parent. In this
context, ‘impact’ is considered in the negative sense, con-
ferring challenges to the parent. The primary aim of this
analysis is to examine the psychometric properties of the
PARimpact as a “stand-alone” scale of the impact of chil-
dren’s BMTs on parents, and parents’ ability to meet
their own needs. A secondary aim is to explore factors
associated with PARimpact scores for further hypothesis
generation.
Methods
Data for this analysis were drawn from a merged dataset
of two completed dyadic longitudinal health-related
quality of life (HRQL) studies comprised of children
undergoing BMT and their accompanying parent(Journeys to Recovery (JTR) and HSCT-CHESS™, de-
scribed elsewhere [16-18]). Data were collected at
eight pediatric BMT centers across the United States
from 2003–2011 at clinically relevant time points:
pre-BMT baseline, 45 days (represents the end of the in-
patient hospitalization period), 3 months (end of the
acute BMT period), 6 months, 9 months (HSCT-CHESS™
only), and one year after transplant (designed to capture
the late complications and recovery period). Both source
studies, including data from the PARimpact Scale de-
scribed in this paper, were approved by the Tufts Medical
Center Institutional Review Board (IRB) and the IRB at
each research center. IRB approval was also obtained
from Tufts Medical Center and Johns Hopkins University
to combine the data for this analysis in accordance with
the Helsinki Declaration.
Survey data in this study were drawn from the CHRIs-
General, a generic HRQL measure with child, adoles-
cent, and parent versions. The CHRIs contains scales to
measure HRQL and related constructs: HRQL scales
measure emotional, physical, and role functioning, which
together represent the multi-dimensional construct of
HRQL [19], while the PARimpact and global QOL scales
measure related constructs. The separate global QOL
scale consists of nine items in which the respondent
rates their overall quality of life in the areas of physical
health, emotional health, and social health [15]. The
CHRIs scales have been extensively validated within the
pediatric BMT population [6,15].
Study sample
Accompanying parents of pediatric patients aged
2 months to 18 years who were scheduled to undergo
BMT at study sites were consecutively recruited. Dyadic
participation of the parent and child was required. Inclu-
sion criteria for parents were: ability to speak/understand
English, at least 18 years old, parent or legal guardian of
the BMT patient, and ability to provide consent to
participate both for him or herself as well as for the
BMT patient. While only parent data were included
in this analysis, age-eligible child participants also
provided assent (participants < 18 years) or consent
(participants ≥ 18 years) for his or her participation.
Overall, 62% of eligible dyads consented to participate.
Common reasons for non-participation included child re-
fusal (27%), parent refusal (44%), and medical reasons (3%).
Participants did not differ from non-participants based on
child age, gender, or race/ethnicity.
A total of 423 parents were enrolled in the JTR and
HSCT-CHESS™ studies; 60 parents of children less than
5 years old were excluded from this analysis because in
the JTR study parents of children in this age group did
not complete the CHRIs, which left 363 parents in this
analysis.
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Parent Impact Scale
The PARimpact was developed as a separate scale within
the parent-proxy version of the CHRIs-General to meas-
ure the response of the parent to the child’s physical and
emotional health needs. The scale consists of four items
with five response options on a frequency-based Likert-
type scale ranging from “none of the time” to “all of the
time” (see Table 1 for PARimpact questions). The scale
scores range from 0–100 with higher scores indicating
greater parent impact. Starting 45 days after transplant
(“day 45” the second data collection point), three add-
itional open-response items were administered alongside
the PARimpact scale items to ascertain the actions that
parents took in the previous seven days as a result of
their child’s BMT. These included the number of missed
work days in the past week due to the child’s health,
missed work days due to the parent’s health, and the
number of days someone came to help the family in the
past week. While these items were not designed to be
part of the scored PARimpact Scale, they are a related
set of items that complement the PARimpact scale.
Among these three items we focused on missed work-
days due to the child’s health for this analysis.
Parent Emotional Functioning
The Parent Emotional Functioning scale within the parent-
proxy CHRIs General consists of seven questions measur-
ing parent mood, anxiety, and distress [5,6,20]. The re-
sponse options for each item utilize a five-point Likert-type
scale. Scale scores range from 0–100 with higher scores de-
noting better emotional functioning. In the JTR study, the
Parent Emotional Functioning scale demonstrated strong
prediction of DSM-IV Axis 1 disorders, based on area
under the receiver operating characteristic curve [21] for
predicting a threshold or sub-threshold disorder from re-
lated modules of the Structured Clinical Interview for
DSM-IVAxis 1 disorders (c-statistic = 0.75) [20].
Parent Global QOL
The parent version of the Global QOL scale of the
CHRIs consists of nine questions designed to captureTable 1 PARimpact items and scores
Pre-BMT baseline scores (Cronbach’s α = 0.83)
n
Summary score* 363
Item summaries
Child’s physical health causes suffering 363
Child’s physical health limits time for parental needs 363
Child’s emotional health causes suffering 363
Child’s emotional health limits time for parental needs 363
*PARimpact is scored from 0–100 with higher scores indicating greater impact.the multidimensionality of QOL as physical, mental, and
social well-being. Responses are measured with a Likert-
type scale with five response options ranging from
“poor” to “excellent.” The scale is scored from 0–100,
with higher scores indicating higher QOL [16].
Parent General Health
The General Health item in the CHRIs is a single sum-
mary item of parents’ general health appraisal. Parents
were asked, “Overall, how would you rate your health”;
response options include a five-point Likert-type scale,
which is scored on a 0–100 scale with higher scores indi-
cating better health. This item has been used extensively in
clinical practice and research [22] and has been found to
be associated with multi-item scales of general health and
other markers of disease and clinical outcomes [23].
Clinical variables
Clinical data were collected at all assessment time points
by trained study staff, using standardized data collection
instruments. All clinical data were reviewed by the study
PI (SKP) for completeness and consistency. Pre-BMT
baseline information included time since diagnosis
(months), disease category (malignant or non-malignant),
and transplant type (related allogeneic, unrelated allogen-
eic, or autologous). In follow up, specific clinical outcomes
variables used in this analysis included early and late BMT
complications, defined below.
Early BMT complications
We assessed early BMT complications with standardized
grading scales that assess both presence or absence and
severity of the following: acute graft versus host disease
(aGVHD) [24]; end organ toxicity, based on the Bearman
Toxicity Scale; [25] and systemic infection, based on the
National Cancer Institute’s Common Toxicity Criteria
for AE, v. 3.0 [26]. Each of the early BMT complica-
tions was dichotomized as follows: grade 2 or higher
aGVHD; Bearman Toxicity Score maximum ratings
of “intermediate” or “poor” within the first 3 months post-
transplant; and grade 3 or higher infection, indicating sys-
temic and/or life-threatening infection.Mean Std. Dev. % Floor % Ceiling
51.41 24.65 2 4
60.54 28.32 6 19
50.96 31.02 15 12
51.24 31.35 13 15
42.91 30.70 20 8
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Late BMT complications were defined as the extent of
chronic graft versus host disease (cGVHD) [27,28] or a
systemic infection that occurred after the 3-month data
observation [26]. The Bearman scale was not designed
for use beyond the 3-month mark post BMT.
Demographic variables
Parents’ demographic data, including age, race/ethnicity,
education, marital status, household income, work status
(e.g., full-time, part-time), and child’s insurance were
collected from parent participants at pre-BMT baseline.
Parents also reported their child’s race/ethnicity and sex.
Statistical analysis
Demographic and clinical characteristics were described
for the combined study sample using medians (inter-
quartile range [IQR]), means (standard deviations [SD]),
frequencies, and percentages at pre-BMT baseline. Par-
ents’ missed work days due to the child’s health were
also summarized, and Spearman’s correlation was used
to compare this open-response item to the PARimpact
scale score from day 45 to 1 year post BMT.
Psychometric properties of the PARimpact scale
Principal component analysis (PCA) was used to deter-
mine the unidimensionality of the PARimpact scale,
based on data collected at pre-BMT baseline. A scree
plot was used to retain components with an Eigen value
greater than 1.00. Exploratory factor analysis (EFA) was
completed to examine factor loadings and uniqueness.
Factor loadings >0.4 were considered acceptable [29].
Pre-BMT baseline raw scores, means, SDs, ceiling and
floor effects, and percent missing were calculated for
each item within the PARimpact. Cronbach’s alpha [30]
was calculated to estimate the internal consistency of
the scale at pre-BMT baseline. For exploratory scale de-
velopment, the minimum acceptable Cronbach’s alpha is
0.7, but for established scales the minimum is 0.8 [31].
Validation of the PARimpact scale
To assess convergent validity of the PARimpact within
the pediatric BMT sample, Pearson correlations were
calculated between the PARimpact and other scales of
the CHRIs General, including Parent Emotional Func-
tioning, Parent Global QOL, and Parent General Health.
Correlations between 0 and .30 were classified as weak,
.30-.60 as moderate, and > .60 as strong [32]. We hy-
pothesized that parent impact would be strongly corre-
lated to parents’ emotional functioning, moderately
correlated with Global QOL, and weakly correlated with
parents’ general health. The correlations were expected
to have negative valence due to the directionality of
the scales (e.g. higher scores for emotional functioningsuggest better functioning, while higher scores for
PARimpact suggest more negative impact).
Expected variation of PARimpact scores by known
groups was explored using clinically important sub-
groups, such as early complications, and later complica-
tions. For known group comparisons, two separate
binary variables were created: (1) Early Complications,
which included aGVHD ≥ grade 2 and/or systemic infec-
tion and/or “intermediate” or “poor” end organ toxicity;
and (2) Late Complications, which included cGVHD
and/or systemic infection.
Regression analysis
We built two models for regression analysis: an early
model and a late model. The early model included data
from pre-BMT baseline, day 45, and 3 months. The late
model included data after 3 months through 12 months
post BMT. In both models, unadjusted longitudinal re-
gressions were completed with demographic and clinical
variables using residual maximum likelihood (REML).
Timing of repeated assessments was calculated as the
number of days since BMT. Based on a likelihood ratio
test (data not shown), time was treated as continuous
rather than categorical. Variables with an estimated coef-
ficient with p ≤ 0.2 were included in the adjusted multi-
variable regression model. In the adjusted multivariable
longitudinal regressions, variables with p > 0.1 were then
removed from the model.
Auto regressive, unstructured, and compound sym-
metry correlation structures were compared using
Akaike information criterion (AIC). To address the pos-
sibility that PARimpact scores may have been missing
not at random (MNAR) over time, we stratified the final
model by the extent and causes of missing data, defining
strata as follows: (1) those with missing data due to a
medical reason (e.g. child too sick) and (2) those with
complete data or those with missing data not due to a
medical reason (e.g., logistical reasons, such as transpor-
tation or work-related issues). The stratified models
(called pattern mixture models, PMM) [33] assume the
data are missing at random (MAR) within strata. We
compared the stratified to the unstratified model using a
likelihood ratio test to assess for the presence of MNAR.
SAS version 9.3 was used for all statistical analyses;
alpha was set at 0.05.
Results
Study sample
Pre-BMT baseline demographic and clinical characteris-
tics are shown in Table 2. The majority of the sample
was female and Caucasian with at least some college
education. Most parents reported being married or living
with a partner (80%), and reported having at least one
additional child besides the BMT recipient (84%).
Table 2 Participant characteristics
Mean Standard Dev.
Child age 9.6 5.1
Parent age 38.7 7.5
Length of illness (months) 11 (Median) 5, 37 (Q1, Q3)
Patient Parent
n Percent n Percent
Sex
Female 169 47 301 83
Male 194 53 62 17
Race
White 291 81 277 77
Black 24 7 21 6
Asian 11 3 13 4
Other 32 9 47 13
Hispanic ethnicity
Yes 63 18 64 18
No 297 83 297 82
n Percent
Parent marital status
Married/living together 292 80
Divorced/separated/widowed 49 14
Never married 18 5
Other 4 1
Family income
<$20,000 31 9
$20,000-$39,999 89 25
$40,000-$79,000 114 32
$80,000 + 123 34
Child’s insurance
Private 235 65
Public 121 33
None/unknown 7 2
Parent education
< High school 21 6
High school graduate 91 25
Some college 108 30
College graduate + 143 39
Number of siblings
0 60 17
1 134 37
2 or more 169 47
BMT type
Autologous 82 23
Allogeneic – related 89 25
Allogeneic – unrelated 192 53
Table 2 Participant characteristics (Continued)
BMT source
Bone marrow 200 55
Peripheral blood 126 35
Umbilical cord blood 35 10
Other/combined 2 1
Death of child within 12 months
Yes 63 17
No 300 83
Disease relapse within 12 months
Yes 48 13
No 315 87
Heinze et al. Health and Quality of Life Outcomes  (2015) 13:46 Page 5 of 8PARimpact scores
Table 1 displays PARimpact scale and item means, SDs,
and floor and ceiling effects at pre-BMT baseline. For
each item, the full range of possible responses from 0–
100 was utilized. Variability across the scale’s items was
similar (SD 28.3-31.4). Responses at the floor and ceiling
were <5% for the summary score, and ≤20% for the indi-
vidual items; there were no missing data at pre-BMT
baseline.
Table 3 displays open responses to the item, “In the
past week, how many days have you missed work or cut
down on usual activities due to this child’s health?” At
45 days after BMT, 68% of parents reported missing
work or cutting down usual activities at least one day in
the previous week. At 3 months this value was 61%, and
at one year, it was 33%. This item was moderately corre-
lated with the PARimpact scale score, with Spearman’s
Rank correlation values ranging from 0.28-0.57 across
time measurements.
Psychometric properties
PCA and EFA
PCA indicated a single component with an Eigen value of
2.6; all other Eigen values were less than 1.0. This compo-
nent, “PARimpact,” explained 66% of the variation in the
PARimpact scale. In the EFA, factor loadings ranged from
0.60 to 0.88, and uniqueness was <0.20. At pre-BMT base-
line Cronbach’s alpha was 0.83, and at follow-up time
points Cronbach’s alpha ranged from 0.84 – 0.90.Table 3 Parent self-reported days of missed work/decreased
usual activity
Number of days Day 45
n(%)
3 months
n(%)
6 months
n(%)
12 months
n(%)
0 93 (32) 111 (40) 140 (55) 156 (68)
1-3 53 (18) 70 (25) 61 (24) 44 (20)
4-7 146 (50) 100 (36) 55(21) 29 (13)
Table 5 Estimated coefficients for adjusted multivariable
pattern mixture models
Estimate SE p-value
Early (start of BMT – 3 months)
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The PARimpact and Parent Emotional Functioning
scales were strongly correlated (−0.57 to −0.67) across
time periods. The Pearson correlation for PARimpact
and Global QOL ranged from −0.49 to −0.63 across time
periods. General Health, which was hypothesized to be
the least conceptually similar to PARimpact, was weakly
or moderately correlated with PARimpact; Pearson’s
correlation ranged from −0.18 to −0.45 across time pe-
riods (see Table 4 for correlation coefficients at all time
measurements).
Discriminant validity: results of known groups comparisons
Among parents completing the 3-month assessment,
71 (37%) BMT patients had early BMT complications.
Parents of these children had a PARimpact score that
was an average of 11.1 points higher than parents whose
children did not experience early complications (t = 3.75;
p < 0.01). Among parents completing the 12-month as-
sessment, 86 (37%) experienced late BMT complications;
parents whose children experienced late BMT complica-
tions averaged 6.8 points higher (t = 1.91; p = 0.06) than
parents whose children did not.
Regression analysis
Unadjusted analysis
In the early model, none of the demographic variables
met the criteria to be included in the adjusted model.
Among the early complication clinical variables, aGVHD
(p < 0.01), Bearman Toxicity Score (p < 0.01), and sys-
temic infection (p < 0.01) met the criteria to be included
in the adjusted model.
In the late model, parent sex (p = 0.05) was the only
demographic variables to be included in the adjusted
model. Among the late complication clinical variables,
systemic infection (p < 0.01) was the only variable to be
included in the adjusted model.
Adjusted multivariable analysis
Based on AIC, a compound symmetry correlation struc-
ture was selected for the final model. Results of the like-
lihood ratio test comparing the PMM to the repeated
measures model indicated the presence of MNAR (Early:
χ2 (5) =12.7, p = 0.03; Late: χ2 (3) = 16.7, p<0.01),
therefore PMM estimates were used in the final models.Table 4 Correlation coefficients for PARimpact, Global
QOL, and General Health
Pre-BMT Day 45 3 months 6 months 1 year
Parent Emotional
Functioning
−0.57 −0.66 −0.60 −0.67 −0.66
Parent Global QOL −0.49 −0.50 −0.57 −0.58 −0.63
Parent General Health −0.18 −0.25 −0.37 −0.31 −0.45Estimated coefficients from the final models are dis-
played in Table 5.
In the Early model, parents of children who experi-
enced ≥ grade 2 aGVHD had a mean PARimpact score
that was 5 points higher than parents of children who
did not (p = 0.03). Furthermore, PARimpact scores aver-
aged nearly 6 points higher among parents of children
who had Bearman Toxicity Score of “intermediate” or
“poor” (p < 0.01); and scores averaged 9 points higher
among parents of children who experienced a systemic
infection in the first 3 months following BMT (p < 0.01).
In the Late model, parent sex did not meet the criteria
to be retained in the final model (p = 0.15). Among par-
ents of children who experienced a systemic infection,
mean PARimpact scores were 19 points higher than par-
ents of children who did not experience a systemic in-
fection (p < 0.01).
Discussion
This study introduced the Parent Impact Scale, a four-
item scale of the CHRIs General parent-proxy version. A
scree plot and Eigen values supported a single factor so-
lution, and PCA indicated a single factor explained more
than 60% of variation. Factor loadings and uniqueness
were acceptable, and the PARimpact scale demon-
strated a strong coefficient of internal consistency
reliability (α = 0.83).
The PARimpact also demonstrated hypothesized con-
vergent and known groups validity. Specifically, the scale
was strongly associated with global QOL and parent
emotional functioning, but not with general health
scales. In known group comparisons higher PARimpact
scores were noted among parents whose children experi-
enced early and late BMT complications (p < 0.01 and
p = 0.06, respectively).
The additional open-response item of the PARimpact,
assessed in follow-up time points, reveals that a high
percentage of parents did miss work and/or cut down
on usual activities during the year following BMT. This
study is among the first to describe parents’ workTime −0.07 0.02 <0.01
aGVHD≥ grade 2 5.31 2.48 0.03
Bearman Toxicity 5.91 1.97 <0.01
Systemic infection 9.09 2.09 <0.01
Late (after 3 months - 1 year)
Time −0.02 0.01 0.02
Systemic infection 19.18 3.14 <0.01
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plant. By 3 months post BMT, more than 2/3 of parents
took at least one day off of work and/or cut down on
usual activities during the week prior to the assessment
due to the child’s health; by one year post BMT, nearly
1/3 of parents had taken off at least one day of work – a
finding that reflects the high role disruption and associ-
ated economic burden that BMT places on families. This
is consistent with other studies that have found more
than one year after BMT, families of children who had
BMT experience a greater financial impact than families
of children who underwent treatment for leukemia, but
did not require BMT [13]; and that 5–10 years after
BMT, families of children who underwent BMT reported
more financial strain than families of children with on-
cologic diagnoses who did not undergo BMT [11].
PMMs, which accounted for MNAR, showed mean
PARimpact scores were significantly increased with clin-
ical BMT complications, such as moderate to severe
GVHD, “intermediate” or “poor” end organ toxicity, and
systemic infection, which is consistent with other find-
ings that parent emotional functioning declined with
BMT clinical complications [5]. Systemic infection was
associated with significantly higher mean PARimpact
scores in both early and late models (9 points and 19
points higher respectively), which may be an indication
of the distress and disruption that can be associated with
a life-threatening complication like systemic infection at
any point in the recovery trajectory. A more complete
understanding of the durability of parent vulnerability
after BMT could lead to the development of interven-
tions to decrease parent impact during and after BMT.
In a retrospective study more than one year after BMT,
parents indicated that education related to taking care of
themselves would be helpful to parents during the BMT
process [34].
Strengths and limitations
This study represents eight years of research; it is
strengthened by the power of the large sample. Although
the majority of the sample was White/Non-Hispanic
(70%), as is typical of studies in this clinical population,
the study team was able to recruit more than 27% Non-
White or Hispanic participants. Study participants also
had high educational attainment and income. The longi-
tudinal design strengthens study findings, as does the
completeness of clinical outcomes data even when
patient-reported outcomes were missed. Nevertheless, as
would be expected in a longitudinal study in a critically
ill population, some study participants were lost to
follow-up, principally due to the child’s death or relapse.
Rigorous study procedures were used to mitigate loss to
follow-up for non-medical reasons, and PMMs were
used to account for data MNAR.Another important limitation of the current study is
that all of the survey measures used to assess the con-
vergent validity of the PARimpact were self-reported by
parent participants. This can result in shared variance,
which may inflate measures of construct validity. Related
data on missed work were also self-reported. However,
we used clinical variables to examine known group val-
idity, which were not parent reported. Finally, it is pos-
sible that there are other variables that contribute to
parent impact during a child’s BMT that were not in-
cluded in the PARimpact scale.
Conclusion
The promising psychometric properties of the PARimpact
scale indicate that parent impact is a unidimensional con-
struct with clinical relevance. Our findings that early and
late BMT complications, such as systemic infection, signifi-
cantly increase the impact of BMT on the caretaking par-
ent indicate the need for BMT healthcare professionals to
identify these events and help parents navigate the BMT
course. At minimum, BMT healthcare professionals should
be mindful of the additional burden on the parent that
complications bring, and proactively link parents to re-
sources to help them cope with the added impact. Further
study is needed to test the validity of the PARimpact scale
in other populations of caretaking parents of children with
serious illnesses.
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